These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28718401)

  • 1. Targeting ATF5 in Cancer.
    Angelastro JM
    Trends Cancer; 2017 Jul; 3(7):471-474. PubMed ID: 28718401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
    Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
    Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.
    Cates CC; Arias AD; Nakayama Wong LS; Lamé MW; Sidorov M; Cayanan G; Rowland DJ; Fung J; Karpel-Massler G; Siegelin MD; Greene LA; Angelastro JM
    Oncotarget; 2016 Mar; 7(11):12718-30. PubMed ID: 26863637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis.
    Hu M; Wang B; Qian D; Li L; Zhang L; Song X; Liu DX
    Anticancer Res; 2012 Oct; 32(10):4385-94. PubMed ID: 23060563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the human CHOP gene promoter by the stress response transcription factor ATF5 via the AARE1 site in human hepatoma HepG2 cells.
    Yamazaki T; Ohmi A; Kurumaya H; Kato K; Abe T; Yamamoto H; Nakanishi N; Okuyama R; Umemura M; Kaise T; Watanabe R; Okawa Y; Takahashi S; Takahashi Y
    Life Sci; 2010 Aug; 87(9-10):294-301. PubMed ID: 20654631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD.
    Sun X; Jefferson P; Zhou Q; Angelastro JM; Greene LA
    Mol Cancer Res; 2020 Feb; 18(2):216-228. PubMed ID: 31676720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATF5 increases cisplatin-induced apoptosis through up-regulation of cyclin D3 transcription in HeLa cells.
    Wei Y; Jiang J; Sun M; Chen X; Wang H; Gu J
    Biochem Biophys Res Commun; 2006 Jan; 339(2):591-6. PubMed ID: 16300731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers.
    Greene LA; Zhou Q; Siegelin MD; Angelastro JM
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas.
    Arias A; Lamé MW; Santarelli L; Hen R; Greene LA; Angelastro JM
    Oncogene; 2012 Feb; 31(6):739-51. PubMed ID: 21725368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating transcription factor 5 enhances radioresistance and malignancy in cancer cells.
    Ishihara S; Yasuda M; Ishizu A; Ishikawa M; Shirato H; Haga H
    Oncotarget; 2015 Mar; 6(7):4602-14. PubMed ID: 25682872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy?
    Sheng Z; Evans SK; Green MR
    Oncotarget; 2010 Oct; 1(6):457-460. PubMed ID: 21311102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner.
    Dluzen D; Li G; Tacelosky D; Moreau M; Liu DX
    J Biol Chem; 2011 Mar; 286(9):7705-13. PubMed ID: 21212266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and targeting of transcription factor ATF5 in dog gliomas.
    York D; Sproul CD; Chikere N; Dickinson PJ; Angelastro JM
    Vet Comp Oncol; 2018 Mar; 16(1):102-107. PubMed ID: 28480569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines.
    Monaco SE; Angelastro JM; Szabolcs M; Greene LA
    Int J Cancer; 2007 May; 120(9):1883-90. PubMed ID: 17266024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATF5 promotes cell survival through transcriptional activation of Hsp27 in H9c2 cells.
    Wang H; Lin G; Zhang Z
    Cell Biol Int; 2007 Nov; 31(11):1309-15. PubMed ID: 17606386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest.
    Gho JW; Ip WK; Chan KY; Law PT; Lai PB; Wong N
    Cancer Res; 2008 Aug; 68(16):6743-51. PubMed ID: 18701499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma.
    Wang M; Hu M; Li Z; Qian D; Wang B; Liu DX
    Biochem Biophys Res Commun; 2017 Sep; 490(4):1260-1267. PubMed ID: 28595907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP70 protein promotes survival of C6 and U87 glioma cells by inhibition of ATF5 degradation.
    Li G; Xu Y; Guan D; Liu Z; Liu DX
    J Biol Chem; 2011 Jun; 286(23):20251-9. PubMed ID: 21521685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells.
    Li G; Li W; Angelastro JM; Greene LA; Liu DX
    Mol Cancer Res; 2009 Jun; 7(6):933-43. PubMed ID: 19531563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of the promoter of human ATF5 gene.
    Wei Y; Ge Y; Zhou F; Chen H; Cui C; Liu D; Yang Z; Wu G; Gu J; Jiang J
    J Biochem; 2010 Aug; 148(2):171-8. PubMed ID: 20423929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.